Evidence map›Paper›PMID 42227000›Full record

ArticleJournal of patient experience2026

A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast Cancer.

Amy Beumer, Martha Carlson, Abby L Arcuri, Julia Maues, Janice Cowden, Stephanie Walker, Kelly Shanahan, Jo Lynn Collins, A J Veach, Hope S Rugo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of patient experience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Amy BeumerPatient Centered Dosing Initiative, Washington DC, USA.
Martha CarlsonPatient Centered Dosing Initiative, Washington DC, USA.ORCID https://orcid.org/0009-0008-7994-6443
Abby L ArcuriDepartment of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Julia MauesPatient Centered Dosing Initiative, Washington DC, USA.
Janice CowdenPatient Centered Dosing Initiative, Washington DC, USA.
Stephanie WalkerPatient Centered Dosing Initiative, Washington DC, USA.
Kelly ShanahanPatient Centered Dosing Initiative, Washington DC, USA.
Jo Lynn CollinsPatient Centered Dosing Initiative, Washington DC, USA.
A J VeachPatient Centered Dosing Initiative, Washington DC, USA.
Hope S RugoCity of Hope Cancer Center, Duarte, CA, USA.
Mark E BurkardUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.
Kevin M KalinskyEmory Winship Comprehensive Cancer Center, Atlanta, GA, USA.
Aditya BardiaUniversity of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
Maryam B LustbergYale Cancer Center, New Haven, CT, USA.
Elizabeth Lerner PapautskyBiomedical and Health Information Sciences, College of Applied Health Sciences, University of Illinois Chicago, Chicago, IL, USA.ORCID https://orcid.org/0000-0003-2771-9579
Mya L RobersonDepartment of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID https://orcid.org/0000-0002-9908-910X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scientific advancements have led to more people living longer with metastatic breast cancer (MBC). Antibody-drug conjugates (ADCs) offer a promising treatment option, but currently approved ADCs are associated with significant side effects that can impact quality of life. Dose reductions may help mitigate these effects, yet little is known about real-world, patient-reported experiences with ADC dosing. We surveyed 170 individuals with MBC who had received ADC treatment to assess initial dosing, dose modifications, and barriers to supportive care. Most respondents (94.1%) began treatment with the recommended dosing frequency and 82.9% with the recommended dose. However, 35.3% reported dose reductions, primarily due to experienced or anticipated side effects. Open-ended responses underscored the burden of side effects: "If not for low dose, I don't think I could go on." Most participants (81.0%) reported oncologist-led efforts to manage side effects, and 73.0% used medications for symptom control. Financial barriers were common, with 43.5% reporting difficulty accessing supportive care. These findings highlight the need for patient-centered dosing strategies and improved access to supportive care.

Indexed as

metastatic breast cancerpatient engaged researchprecision medicine

Identifiers

PMID42227000
PMCPMC13222401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.